Peregrine Adds Study Site for Bavituximab Trial

Peregrine Pharmaceuticals has added Johns Hopkins Hospital in Baltimore, Md., to its trial evaluating bavituximab in patients co-infected with hepatitis C virus (HCV) and HIV.

The open-label, dose-escalation study is expected to enroll up to 24 patients. Patient cohorts will receive ascending dose levels of bavituximab weekly for up to eight weeks.

HCV and HIV viral titers and other biomarkers will be evaluated although they are not formal study endpoints, Peregrine said.